title: Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates.
abstract: Alendronate has been approved as a first antiresorptive drug for treatment of osteoporosis in men. Except for fluoride, in some countries so far there has been no approved anabolic substance for the treatment of male osteoporosis. From small studies in men and male patients included in studies on postmenopausal osteoporosis there is sufficient evidence that fluoride has the same osteoblast-stimulating potency in men and women. In our own study on 64 men with idiopathic osteoporosis without prevalent fractures, a low-dose intermittent fluoride regimen (15 mg fluoride ions 3 months on, 1 month off) resulted in an average gain of lumbar spine BMD of 3% per year and a lower rate of incident fractures as compared with patients treated with calcium only. A combination of fluoride with an antiresorptive drug may improve the therapeutic results in terms of pattern of biochemical marker response and gain in BMD. This was shown for postemopausal osteoporosis in several studies using fluoride and hormone replacement therapy (HRT). Encouraged by a Dutch study using etidronate/fluoride in corticoid-induced osteoporosis, we performed a pilot study in 33 men with severe established primary osteoporosis giving cyclically etidronate for 14 days followed by fluoride plus calcium/vitamin D for 76 days. This combined regimen resulted in significantly higher increases of BMD than fluoride or etidronate alone. In an ongoing trial we are studying a continuous, combined treatment of alendronate and fluoride plus calcium/vitamin D in established idiopathic osteoporosis in men. The results of a preliminary evaluation look very promising. A large study with a bisphosphonate plus fluoride, taking fractures as the primary endpoint and bone biopsies to assess safety, would be very valuable.
authors.affiliation: Klinikum Leverkusen, University of Cologne, Germany.
authors.forename: J D
authors.initials: JD
authors.lastname: Ringe
authors.forename: L C
authors.initials: LC
authors.lastname: Rovati
mesh_terms: D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D002979:Climacteric / Q000502:physiology; D004359:Drug Therapy, Combination; D012968:Etidronic Acid / Q000627:therapeutic use*; D005459:Fluorides / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism; D010865:Pilot Projects
chemical_list: D012968:Etidronic Acid; D005459:Fluorides; D019386:Alendronate